Cargando…
Predicting STAT1 as a prognostic marker in patients with solid cancer
BACKGROUND: Aberrant activities of signal transducer and activator of transcription 1 (STAT1) have been implicated in cancer development. However, the prognostic value of STAT1 remains unclear. This report identified the role of STAT1 in prognosis in patients with solid cancer through open literatur...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222261/ https://www.ncbi.nlm.nih.gov/pubmed/32426049 http://dx.doi.org/10.1177/1758835920917558 |
_version_ | 1783533534513725440 |
---|---|
author | Zhang, Jinguo Wang, Fanchen Liu, Fangran Xu, Guoxiong |
author_facet | Zhang, Jinguo Wang, Fanchen Liu, Fangran Xu, Guoxiong |
author_sort | Zhang, Jinguo |
collection | PubMed |
description | BACKGROUND: Aberrant activities of signal transducer and activator of transcription 1 (STAT1) have been implicated in cancer development. However, the prognostic value of STAT1 remains unclear. This report identified the role of STAT1 in prognosis in patients with solid cancer through open literature and The Cancer Genome Atlas (TCGA) database. METHODS: Published articles were obtained from PubMed, Web of Science, and Embase databases according to a search strategy up to October 2019. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were extracted to assess the prognostic factors of patients. TCGA datasets were used to explore the prognostic value of STAT1 in various cancers. RESULTS: A total of 15 studies incorporating 2839 patients with solid cancers were included. Pooled data showed that overexpressed STAT1 favored long overall survival (OS) (HR = 0.604, 95% CI = 0.431–0.846, p = 0.003) and disease-specific survival (DSS) (HR = 0.650, 95% CI = 0.512–0.825, p = 0.000). In subgroup analyses, highly expressed STAT1 was correlated with long OS of patients with high-grade serous ovarian cancer and oral squamous cell carcinoma. Data extracted from TCGA datasets unveiled that STAT1 expression was significantly higher in 12 cancers (e.g. bladder and breast) than their adjacent normal tissues. Again, highly expressed STAT1 favored long OS of patients with ovarian cancer as well as rectum adenocarcinoma, sarcoma, and skin cutaneous melanoma. However, in renal carcinoma, brain lower grade glioma, lung adenocarcinoma, and pancreatic cancer, highly expressed STAT1 was correlated with poor OS of patients. Particularly in renal carcinoma, increased STAT1 expression was associated with high grade, later stage, large tumor size, and lymph node and distant metastasis. CONCLUSION: STAT1 has been identified to have prognostic value in patients with solid cancer. Highly expressed STAT1 may predict prognosis in cancer patients based on their tumor types. |
format | Online Article Text |
id | pubmed-7222261 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-72222612020-05-18 Predicting STAT1 as a prognostic marker in patients with solid cancer Zhang, Jinguo Wang, Fanchen Liu, Fangran Xu, Guoxiong Ther Adv Med Oncol Meta-Analysis BACKGROUND: Aberrant activities of signal transducer and activator of transcription 1 (STAT1) have been implicated in cancer development. However, the prognostic value of STAT1 remains unclear. This report identified the role of STAT1 in prognosis in patients with solid cancer through open literature and The Cancer Genome Atlas (TCGA) database. METHODS: Published articles were obtained from PubMed, Web of Science, and Embase databases according to a search strategy up to October 2019. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were extracted to assess the prognostic factors of patients. TCGA datasets were used to explore the prognostic value of STAT1 in various cancers. RESULTS: A total of 15 studies incorporating 2839 patients with solid cancers were included. Pooled data showed that overexpressed STAT1 favored long overall survival (OS) (HR = 0.604, 95% CI = 0.431–0.846, p = 0.003) and disease-specific survival (DSS) (HR = 0.650, 95% CI = 0.512–0.825, p = 0.000). In subgroup analyses, highly expressed STAT1 was correlated with long OS of patients with high-grade serous ovarian cancer and oral squamous cell carcinoma. Data extracted from TCGA datasets unveiled that STAT1 expression was significantly higher in 12 cancers (e.g. bladder and breast) than their adjacent normal tissues. Again, highly expressed STAT1 favored long OS of patients with ovarian cancer as well as rectum adenocarcinoma, sarcoma, and skin cutaneous melanoma. However, in renal carcinoma, brain lower grade glioma, lung adenocarcinoma, and pancreatic cancer, highly expressed STAT1 was correlated with poor OS of patients. Particularly in renal carcinoma, increased STAT1 expression was associated with high grade, later stage, large tumor size, and lymph node and distant metastasis. CONCLUSION: STAT1 has been identified to have prognostic value in patients with solid cancer. Highly expressed STAT1 may predict prognosis in cancer patients based on their tumor types. SAGE Publications 2020-05-08 /pmc/articles/PMC7222261/ /pubmed/32426049 http://dx.doi.org/10.1177/1758835920917558 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Meta-Analysis Zhang, Jinguo Wang, Fanchen Liu, Fangran Xu, Guoxiong Predicting STAT1 as a prognostic marker in patients with solid cancer |
title | Predicting STAT1 as a prognostic marker in patients with solid cancer |
title_full | Predicting STAT1 as a prognostic marker in patients with solid cancer |
title_fullStr | Predicting STAT1 as a prognostic marker in patients with solid cancer |
title_full_unstemmed | Predicting STAT1 as a prognostic marker in patients with solid cancer |
title_short | Predicting STAT1 as a prognostic marker in patients with solid cancer |
title_sort | predicting stat1 as a prognostic marker in patients with solid cancer |
topic | Meta-Analysis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222261/ https://www.ncbi.nlm.nih.gov/pubmed/32426049 http://dx.doi.org/10.1177/1758835920917558 |
work_keys_str_mv | AT zhangjinguo predictingstat1asaprognosticmarkerinpatientswithsolidcancer AT wangfanchen predictingstat1asaprognosticmarkerinpatientswithsolidcancer AT liufangran predictingstat1asaprognosticmarkerinpatientswithsolidcancer AT xuguoxiong predictingstat1asaprognosticmarkerinpatientswithsolidcancer |